Alan Nurden: Genome-Wide Analyses Unravel the Genetic Architecture of Coagulation and Fibrinolysis
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Maria Sabater-Lleal et al, published in JTH:
“This is a very complete review of a very important field, explaining how genome-wide analyses are unraveling the genetic architecture responsible for the levels of the main cellular and plasma factors that regulate coagulation and fibrinolysis.
The authors combine this with a brief look at global coagulation tests, all this in the context of how multiple gene variants influence venous and arterial thrombosis.
Step by step we are approaching the day when whole genome sequencing will become the norm and a prerequisite for personalized medicine.
In my own field of inherited platelet disorders and in particular Glanzmann thrombasthenia, the polygenic scores of gene variants either favoring or protecting from excessive and frequent mucocutaneous bleeding should help select patients most apt for gene therapy or to receive new generation long-term prophylaxis designed to upgrade fibrin formation at sites of bleeding.
For the latter, determining the therapy dose will be crucial in assuring safety.
This review is highly recommended for all in the coagulation and hemostasis fields.”
Title: Historical review: more than two decades understanding the genetic architecture of hemostasis and thrombosis
Authors: Maria Sabater-Lleal, Florian Thibord, Paul S de Vries, Jennifer Huffman, Alisa S Wolberg, Charles J Lowenstein, Alanna C Morrison, Andrew D Johnson, Nicholas L Smith
Read the Full Article on JTH

Other articles featuring Alan Nurden on Hemostasis Today.
-
Apr 30, 2026, 06:06Shashank Joshi: The Emerging Role of Inflammatory Biomarkers in Acute CVS Thrombosis
-
Apr 30, 2026, 05:30John Bramble: Ensuring Safe AI Integration in Medicine
-
Apr 30, 2026, 04:55Danielle Stull: Raising Awareness of CVS Thrombosis in Young Women
-
Apr 29, 2026, 17:25Robert Brodsky: Ravulizumab Appears To Be Safe And Effective In Pregnancy
-
Apr 29, 2026, 16:53Chokri Ben Lamine: IV Iron Showdown – FCM vs Ferric Derisomaltose vs Iron Dextran
-
Apr 29, 2026, 16:46Deep Vein Thrombosis Risk in Jobs with Prolonged Sitting – NBCA
-
Apr 29, 2026, 16:41Vikramaditya Gangakar: Essential Pharmacy Facts You Should Know About Aspirin
-
Apr 29, 2026, 16:17W. Alberto Sifuentes Giraldo: Non-Criteria Manifestations of Antiphospholipid Syndrome
-
Apr 29, 2026, 16:12Mavis Agnes Kisakye: Concluding a Successful Entrepreneurs Training for Empowering Ptients’ Mothers